Evidence map›Paper›PMID 41359057›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Novel cyclic heptapeptides as potential therapeutics against methicillin-resistant Staphylococcus aureus infections.

Mohammed Sharif Shaik, Vidya Sagar Jerra, Balajee Ramachandran, Srinivasadesikan Venkatesan

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohammed Sharif ShaikDepartment of Chemistry, School of Applied Science and Humanities, Vignan's Foundation for Science Technology and Research, Vadlamudi - 522213, Guntur, Andhra Pradesh, India.
Vidya Sagar JerraDepartment of Chemistry, School of Applied Science and Humanities, Vignan's Foundation for Science Technology and Research, Vadlamudi - 522213, Guntur, Andhra Pradesh, India.
Balajee RamachandranDepartment of Pharmacology, Physiology & Biophysics, Boston University Chobanian and Avedisian School of Medicine, 700 Albany Street, Boston, MA, 02118, USA.
Srinivasadesikan VenkatesanDepartment of Chemistry, School of Applied Science and Humanities, Vignan's Foundation for Science Technology and Research, Vadlamudi - 522213, Guntur, Andhra Pradesh, India. drvsd_sh@vignan.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel therapeutic agents for methicillin-resistant Staphylococcus aureus (MRSA) need to be developed because of the growing antibacterial resistance against MRSA. This study aimed to design and develop novel cyclic heptapeptides as potential antibacterial agents with improved efficacy and safety profiles against MRSA. Here, we designed 100 novel cyclic heptapeptides, and it was examined computationally and validated through experimental methods. The best three cyclic heptapeptides, such as Tyr

Indexed as

Anti-Bacterial AgentsMethicillin-Resistant Staphylococcus aureusPeptides, CyclicDrug DesignHemolysisHumansMicrobial Sensitivity TestsStaphylococcal InfectionsStructure-Activity RelationshipAnti-Bacterial AgentsPeptides, CyclicADMET parametersAntibacterial activityCyclic heptapeptideDFT studiesHTSMD simulationMRSAPeptide synthesis

Identifiers

PMID41359057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.